Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 17-20

  Vecchi, Simone ^a   Bufali, Simone ^a   Skibinski, David A G ^a   O'hagan, Derek T ^b   Singh, Manmohan ^b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Injectables; Preformulation; Protein formulation; Vaccine adjuvants; Vaccines

Indexed keywords

ALUMINUM SALT; ANTIGEN; VACCINE;

DRUG FORMULATION; NOTE; PRACTICE GUIDELINE;

EID: 82255175801     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22759     Document Type: Note

References (21)

1. Braun LJ, Clapp T, Siebert P, Chen DX. 2011. Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability. J Pharm Sci 100(2):388-401.
2. Mbow M, De Gregorio E, Ulmer J. 2011. Alum's adjuvant action: Grease is the word. Nat Med 17(4):415-416.
3. Glenny A, Pope C, Waddington H, Wallace U. 1926. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 29:38-45.
4. Committe for Medicinal Products for Human Use 2005. Guideline on adjuvants in vaccines for human use. EMEA/CHMP/VEG/134716/2004.
5. Gupta RK, Rost BE, Relyveld E, Siber GR. 1995. Adjuvant properties of aluminum and calcium compounds. In Vaccine design: The subunit and adjuvant approach; Powell MF, Newman MJ, Eds. New York: Plenum Press, pp 229-248.
6. Johnston CT, Wang SL, Hem SL. 2002. Measuring the surface area of aluminum hydroxide adjuvant. J Pharm Sci 91(7):1702-1706.
7. Burrell LS, Johnston CT, Schulze D, Klein J, White JL, Hem SL. 2000. Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part I: Composition and structure. Vaccine 19(2-3):275-281.
8. Burrell LS, Johnston CT, Schulze D, Klein J, White JL, Hem SL. 2000. Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part II: Physicochemical properties. Vaccine 19(2-3):282-287.
9. Hem SL, Esch HH. 2007. Aluminum-containing adjuvants: properties, formulation and use. In Vaccine adjuvants and delivery systems; Singh M, Ed. Hoboken: John Wiley & Sons, Inc. pp 81-114.
10. White AH, Hem SL. 2000. Characterization of aluminum-containing adjuvants. In Physico-chemical procedures for the characterization of vaccines; Brown F, Corbel MJ, Griffiths E, Eds. Basel: Karger, pp 217-228.
11. Lindblad EB, Schonberg NE. 2010. Aluminum adjuvants: Preparation, application, dosage, and formulation with antigen. In Vaccine adjuvants, methods in molecular biology; Davies G, Ed. New York: Humana Press, pp 41-58.
12. Glemza R, Parent YO, Welsh WA. 1992. Amorphous aluminum phosphate gels. Catalysis Today 14(2):175-188.
13. Gupta RK, Rost BE. 2000. Aluminum compounds as vaccine adjuvants. In Vaccine adjuvants: Preparation methods and research protocols; O'Hagan DT, Ed. Totowa, New Jersey: Humana Press, pp 65-89.
14. Wolf JJ, Kaplanski CV, Lebron JA. 2010. Nonclinical safety assessment of vaccines and adjuvants. In Vaccine adjuvants methods in molecular biology; Davies G, Ed. New York: Humana Press, pp 29-40.
15. Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA. 1997. In vivo absorption of aluminium-containing vaccine adjuvants using Al-26. Vaccine 15(12-13):1314-1318.
16. Titkov AN, Oganesyan GA. 1995. Chronic effects of high doses of intramuscularly injected aluminium on the nervous system and hear activity in rats. J Evol Biochem Physiol 31(1):32-38.
17. Hansen B, Sokolovska A, HogenEsch H, Hem SL. 2007. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25(36):6618-6624.
18. Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, HogenEsch H, Mancinelli R, Hem SL. 2009. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 27(6):888-892.
19. Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. 2007. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 25(5):825-833.
20. Matheis W, Zott A, Schwanig M. 2001. The role of the adsorption process for production and control combined adsorbed vaccines. Vaccine 20(1-2):67-73.
21. Brito LA, Singh M. 2011. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci 100(1):34-37.